
Aurélien Delluc

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7289317/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2022, 122, 830-841.	3.4	10
2	Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. Journal of Thrombosis and Haemostasis, 2022, 20, 126-132.	3.8	6
3	Rivaroxaban vsÂDalteparin in Cancer-Associated Thromboembolism. Chest, 2022, 161, 781-790.	0.8	75
4	Evaluation of the PADIS score stratifying risk for venous thromboembolism recurrence after a first unprovoked pulmonary embolism: results from the REVERSE study. European Respiratory Journal, 2022, 59, 2101801.	6.7	0
5	Prevention of the Postthrombotic Syndrome with Anticoagulation: A Narrative Review. Thrombosis and Haemostasis, 2022, 122, 1255-1264.	3.4	10
6	External Validation of the Patient-Reported Villalta Scale for the Diagnosis of Postthrombotic Syndrome. Thrombosis and Haemostasis, 2022, 122, 1379-1383.	3.4	4
7	Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER). Thrombosis Research, 2022, 213, 119-124.	1.7	4
8	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Advances, 2022, 6, 3569-3578.	5.2	19
9	Source of upper gastrointestinal bleeding in cancer patients: A cross-sectional study. Thrombosis Research, 2022, 217, 9-11.	1.7	0
10	Challenging anticoagulation cases: A case of incidental subsegmental pulmonary embolism in a patient with cancer. Thrombosis Research, 2021, 197, 77-83.	1.7	2
11	Detection of right ventricular dysfunction in acute pulmonary embolism by computed tomography or echocardiography: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2504-2513.	3.8	9
12	Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2021, 19, 2468-2479.	3.8	21
13	ISTH definition of pulmonary embolismâ€related death and classification of the cause of death in venous thromboembolism studies: Validation in an autopsy cohort. Journal of Thrombosis and Haemostasis, 2021, 19, 2514-2521.	3.8	3
14	Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial. Thrombosis Research, 2021, 208, 79-82.	1.7	4
15	Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis. Thrombosis Research, 2021, 208, 58-65.	1.7	5
16	Efficacy and Safety of Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Patients with Cancer and Central Venous Catheter: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 2139-2139.	1.4	0
17	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study. Blood, 2021, 138, 671-671.	1.4	1
18	How to treat incidental pulmonary embolism in cancer patients? Recent advances. Kardiologia Polska, 2021, 79, 1305-1310.	0.6	4

Aurélien Delluc

#	Article	IF	CITATIONS
19	Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica, 2020, 105, 1436-1442.	3.5	19
20	Prevalence of confirmed antiphospholipid syndrome in 18â€50 years unselected patients with first unprovoked venous thromboembolism. Journal of Thrombosis and Haemostasis, 2020, 18, 926-930.	3.8	29
21	Longâ€ŧerm risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUSâ€PTS study. Journal of Thrombosis and Haemostasis, 2020, 18, 857-864.	3.8	24
22	Yield of ultrasonography in patients with or without postâ€thrombotic syndrome for diagnosis of suspected recurrent ipsilateral deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2020, 18, 2654-2657.	3.8	1
23	Arterial and venous thrombosis: What's the link? A narrative review. Thrombosis Research, 2020, 191, 97-102.	1.7	22
24	Thromboprophylaxis in patients with multiple myeloma. British Journal of Haematology, 2020, 190, 493-494.	2.5	0
25	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. Haematologica, 2020, 105, e307-e309.	3.5	3
26	Incidence of upper-extremity deep vein thrombosis in western France: a community-based study. Haematologica, 2019, 104, e29-e31.	3.5	20
27	Management of suspected and confirmed recurrent venous thrombosis while on anticoagulant therapy. What next?. Thrombosis Research, 2019, 180, 105-109.	1.7	13
28	Incidence of Cancer after a Second Unprovoked Venous Thromboembolic Event. Thrombosis and Haemostasis, 2019, 119, 490-495.	3.4	4
29	Anticoagulation of cancer patients with nonâ€valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2019, 17, 1247-1252.	3.8	60
30	Real-world incidence of cancer following a first unprovoked venous thrombosis: Results from the EPIGETBO study. Thrombosis Research, 2018, 164, 79-84.	1.7	18
31	Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. Thrombosis Research, 2018, 171, 92-96.	1.7	20
32	Autosomic dominant familial Behçet disease and haploinsufficiency A20: A review of the literature. Autoimmunity Reviews, 2018, 17, 809-815.	5.8	69
33	Poor outcomes after venous thromboembolism in cancer patients: It's time to change practice. Thrombosis Research, 2018, 171, 177-178.	1.7	0
34	Current incidence of venous thromboembolism and comparison with 1998: a community-based study in Western France. Thrombosis and Haemostasis, 2016, 116, 967-974.	3.4	96
35	External validation of the modified Ottawa score for risk stratification of recurrent cancer-associated thrombosis. European Journal of Internal Medicine, 2016, 36, e11-e12.	2.2	11
36	Limited screening with versus without 18F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial. Lancet Oncology, The, 2016, 17, 193-199.	10.7	83

Aurélien Delluc

#	Article	IF	CITATIONS
37	Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis. Thrombosis Research, 2014, 134, 1214-1219.	1.7	154
38	Body mass index, a major confounder to insulin resistance association with unprovoked venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 593-597.	3.4	8
39	Lipid parameters and venous thromboembolism: clinical evidence, pathophysiology and therapeutic implications. Clinical Lipidology, 2012, 7, 455-469.	0.4	1
40	Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism. Atherosclerosis, 2012, 220, 184-188.	0.8	28
41	Lipid lowering drugs and the risk of recurrent venous thromboembolism. Thrombosis Research, 2012, 130, 859-863.	1.7	35